article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

1ne: A new analysis predicts that by 2030, 48.9% Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed.

article thumbnail

Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023

Pharmaceutical Technology

GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. Omega Therapeutics’s share suggests increasing competition and diversification in this innovative field,” concluded Podder. Global RNA therapy clinical trials market to reach $3.5 subvariant.

Marketing 110
article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

The two companies said the transaction is expected to close by the end of 2022, subject to approval by the competition authorities.

article thumbnail

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Pharmaceutical Technology

4DMT is creating a gene therapy using an adeno-associated viral vector (AAV) and there is currently competition from several early-stage therapies in trial, such as Sangamo Therapeutics’s Fabry gene therapy that is currently at Phase III, which also uses AAV, and as of November 2022 has reported it is progressing to late-stage plans.

FDA 105
article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98
article thumbnail

Five Ways ASCs Can Use Price Transparency to Strengthen Their Market Position

Clarify Health

As both government and commercial payers direct a greater share of volume to out-patient facilities and patient demand for same-day service increases, opportunity and competition in the ambulatory surgical center (ASC) space are increasing. Is there an ASC in your market you should merge with or acquire?